Complementary and alternative medicines in irritable bowel syndrome: An integrative view

World Journal of Gastroenterology

Volumn 20, Issue 2, 2014, Pages 346-362

  Grundmann, Oliver ^a,b   Yoon, Saunjoo L ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF NURSING   (United States)

Author keywords

Cognitive behavioral therapy; Complementary and alternative medicine; Herbal therapy; Hypnotherapy; Irritable bowel syndrome; Peppermint

Indexed keywords

PLANT MEDICINAL PRODUCT;

ACUPUNCTURE; ALTERNATIVE MEDICINE; COGNITIVE THERAPY; HUMAN; HYPNOSIS; IRRITABLE BOWEL SYNDROME; PHYTOTHERAPY; PROCEDURES; TREATMENT OUTCOME; YOGA;

ACUPUNCTURE THERAPY; COGNITIVE THERAPY; COMPLEMENTARY THERAPIES; HUMANS; HYPNOSIS; IRRITABLE BOWEL SYNDROME; PHYTOTHERAPY; PLANT PREPARATIONS; TREATMENT OUTCOME; YOGA;

EID: 84892896574     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i2.346     Document Type: Article

References (185)

1. Rey E, Talley NJ. Irritable bowel syndrome: novel views on the epidemiology and potential risk factors. Dig Liver Dis 2009; 41: 772-780 [PMID: 19665952]
2. Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 Suppl 1: S1-S35 [PMID: 19521341]
3. Talley NJ, Zinsmeister AR, Melton LJ. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995; 142: 76-83 [PMID: 7785677]
4. Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional gastrointestinal disorders in Canada: first populationbased survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 2002; 47: 225-235 [PMID: 11837727]
5. Lacy BE, Weiser K, Noddin L, Robertson DJ, Crowell MD, Parratt-Engstrom C, Grau MV. Irritable bowel syndrome: patients' attitudes, concerns and level of knowledge. Aliment Pharmacol Ther 2007; 25: 1329-1341 [PMID: 17509101]
6. Hungin AP, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005; 21: 1365-1375 [PMID: 15932367]
7. Drossman DA, Morris CB, Schneck S, Hu YJ, Norton NJ, Norton WF, Weinland SR, Dalton C, Leserman J, Bangdiwala SI. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol 2009; 43: 541-550 [PMID: 19384249]
8. Ringel Y, Williams RE, Kalilani L, Cook SF. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2009; 7: 68-72; quiz 3 [PMID: 19124113]
9. Inadomi JM, Fennerty MB, Bjorkman D. Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 671-682 [PMID: 14510740]
10. McFarland LV. State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008. World J Gastroenterol 2008; 14: 2625-2629 [PMID: 18461647]
11. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th revision. Geneve: World Health Organization, 2007
12. Jones J, Boorman J, Cann P, Forbes A, Gomborone J, Heaton K, Hungin P, Kumar D, Libby G, Spiller R, Read N, Silk D, Whorwell P. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 2000; 47 Suppl 2: ii1-i19 [PMID: 11053260]
13. Drossman DA, Douglas A. Rome III: The Functional Gastrointestinal Disorder. 3rd ed. McLean: Degnon Associates, Inc., 2006: 1048
14. Coëffier M, Gloro R, Boukhettala N, Aziz M, Lecleire S, Vandaele N, Antonietti M, Savoye G, Bôle-Feysot C, Déchelotte P, Reimund JM, Ducrotté P. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol 2010; 105: 1181-1188 [PMID: 19997094]
15. Rösch W, Liebregts T, Gundermann KJ, Vinson B, Holtmann G. Phytotherapy for functional dyspepsia: a review of the clinical evidence for the herbal preparation STW 5. Phytomedicine 2006; 13 Suppl 5: 114-121 [PMID: 16978851]
16. Macsharry J, O'Mahony L, Fanning A, Bairead E, Sherlock G, Tiesman J, Fulmer A, Kiely B, Dinan TG, Shanahan F, Quigley EM. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol 2008; 43: 1467-1476 [PMID: 18752146]
17. Scully P, McKernan DP, Keohane J, Groeger D, Shanahan F, Dinan TG, Quigley EM. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 2010; 105: 2235-2243 [PMID: 20407431]
18. Katiraei P, Bultron G. Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome. World J Gastroenterol 2011; 17: 2791-2800 [PMID: 21734786 DOI: 10.3748/wjg.v17.i23.2791]
19. Grundmann O, Yoon SL, Moshiree B. Current developments for the diagnosis and treatment of irritable bowel syndrome. Curr Pharm Des 2010; 16: 3638-3645 [PMID: 21128902]
20. Grundmann O, Yoon SL. Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners. J Gastroenterol Hepatol 2010; 25: 691-699 [PMID: 20074154]
21. Jones MP, Keefer L, Bratten J, Taft TH, Crowell MD, Levy R, Palsson O. Development and initial validation of a measure of perceived stigma in irritable bowel syndrome. Psychol Health Med 2009; 14: 367-374 [PMID: 19444714 DOI: 10.1080/ 13548500902865956]
22. Tang YR, Yang WW, Liang ML, Xu XY, Wang MF, Lin L. Age-related symptom and life quality changes in women with irritable bowel syndrome. World J Gastroenterol 2012; 18: 7175-7183 [PMID: 23326122 DOI: 10.3748/wjg.v18. i48.7175]
23. Mathew P, Bhatia SJ. Pathogenesis and management of irritable bowel syndrome. Trop Gastroenterol 2009; 30: 19-25 [PMID: 19624083]
24. Blanchard EB, Lackner JM, Jaccard J, Rowell D, Carosella AM, Powell C, Sanders K, Krasner S, Kuhn E. The role of stress in symptom exacerbation among IBS patients. J Psychosom Res 2008; 64: 119-128 [PMID: 18222125]
25. Mayer EA, Craske M, Naliboff BD. Depression, anxiety, and the gastrointestinal system. J Clin Psychiatry 2001; 62 Suppl 8: 28-36; discussion 37 [PMID: 12108819]
26. Lackner JM, Ma CX, Keefer L, Brenner DM, Gudleski GD, Satchidanand N, Firth R, Sitrin MD, Katz L, Krasner SS, Ballou SK, Naliboff BD, Mayer EA. Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013; 11: 1147-1157 [PMID: 23524278 DOI: 10.1016/j.cgh.2013.03.011]
27. Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, Gershon MD. Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 1996; 16: 2352-2364 [PMID: 8601815]
28. Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, Crowell MD, Sharkey KA, Gershon MD, Mawe GM, Moses PL. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 1657-1664 [PMID: 15188158]
29. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108: 65-72 [PMID: 11059442]
30. Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J Clin Gastroenterol 2005; 39: S184-S193 [PMID: 15798484]
31. Kern MK, Shaker R. Cerebral cortical registration of subliminal visceral stimulation. Gastroenterology 2002; 122: 290-298 [PMID: 11832444]
32. El-Salhy M, Wendelbo I, Gundersen D. Serotonin and serotonin transporter in the rectum of patients with irritable bowel disease. Mol Med Rep 2013; 8: 451-455 [PMID: 23778763 DOI: 10.3892/mmr.2013.1525]
33. Kumar S, Ranjan P, Mittal B, Ghoshal UC. Serotonin transporter gene (SLC6A4) polymorphism in patients with irritable bowel syndrome and healthy controls. J Gastrointestin Liver Dis 2012; 21: 31-38 [PMID: 22457857]
34. Kapeller J, Houghton LA, Mönnikes H, Walstab J, Möller D, Bönisch H, Burwinkel B, Autschbach F, Funke B, Lasitschka F, Gassler N, Fischer C, Whorwell PJ, Atkinson W, Fell C, Büchner KJ, Schmidtmann M, van der Voort I, Wisser AS, Berg T, Rappold G, Niesler B. First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Mol Genet 2008; 17: 2967-2977 [PMID: 18614545 DOI: 10.1093/hmg/ddn195]
35. Milne RJ, Heel RC. Ondansetron. Therapeutic use as an antiemetic. Drugs 1991; 41: 574-595 [PMID: 1711961]
36. Goldberg PA, Kamm MA, Setti-Carraro P, van der Sijp JR, Roth C. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 1996; 57: 478-483 [PMID: 8913711]
37. Callahan MJ. Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J Clin Gastroenterol 2002; 35: S58-S67 [PMID: 12184141]
38. Smart HL, Mayberry JF, Atkinson M. Alternative medicine consultations and remedies in patients with the irritable bowel syndrome. Gut 1986; 27: 826-828 [PMID: 3755416]
39. Kang SH, Choi SW, Lee SJ, Chung WS, Lee HR, Chung KY, Lee ES, Moon HS, Kim SH, Sung JK, Lee BS, Jeong HY. The effects of lifestyle modification on symptoms and quality of life in patients with irritable bowel syndrome: a prospective observational study. Gut Liver 2011; 5: 472-477 [PMID: 22195246 DOI: 10.5009/gnl.2011.5.4.472]
40. Harris LR, Roberts L. Treatment for irritable bowel syndrome: patients' attitudes and acceptability. BMC Complem Altern Med 2008; 8: 65
41. Langmead L, Chitnis M, Rampton DS. Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflamm Bowel Dis 2002; 8: 174-179 [PMID: 11979137]
42. Hussain Z, Quigley EM. Systematic review: Complementary and alternative medicine in the irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 465-471 [PMID: 16441466 DOI: 10.1111/j.1365-2036.2006.02776.x]
43. Yoon SL, Grundmann O, Koepp L, Farrell L. Management of irritable bowel syndrome (IBS) in adults: conventional and complementary/alternative approaches. Altern Med Rev 2011; 16: 134-151 [PMID: 21649455]
44. Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, Kowalczykowski M, Miller FG, Kirsch I, Lembo AJ. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One 2010; 5: e15591 [PMID: 21203519 DOI: 10.1371/journal. pone.0015591]
45. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tri-cyclic antidepressants in irritable bowel syndrome: a metaanalysis. World J Gastroenterol 2009; 15: 1548-1553 [PMID: 19340896]
46. Halpert A, Dalton CB, Diamant NE, Toner BB, Hu Y, Morris CB, Bangdiwala SI, Whitehead WE, Drossman DA. Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 2005; 100: 664-671 [PMID: 15743366]
47. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and metaanalysis. Gut 2009; 58: 367-378 [PMID: 19001059]
48. Käll E, Lindström E, Martinez V. The serotonin reuptake inhibitor citalopram does not affect colonic sensitivity or compliance in rats. Eur J Pharmacol 2007; 570: 203-211 [PMID: 17594902]
49. Salari P, Abdollahi M. Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: is there hope? World J Gastroenterol 2011; 17: 4251-4257 [PMID: 22090780 DOI: 10.3748/wjg.v17.i38.4251]
50. Camilleri M. Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome. Expert Opin Pharmacother 2013; 14: 1151-1160 [PMID: 23621801 DOI: 10.1517/14656566.2013.794223]
51. Heizer WD, Southern S, McGovern S. The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review. J Am Diet Assoc 2009; 109: 1204-1214 [PMID: 19559137 DOI: 10.1016/j.jada.2009.04.012]
52. Lea R, Whorwell PJ. The role of food intolerance in irritable bowel syndrome. Gastroenterol Clin North Am 2005; 34: 247-255 [PMID: 15862933]
53. Gholamrezaei A, Ardestani SK, Emami MH. Where does hypnotherapy stand in the management of irritable bowel syndrome? A systematic review. J Altern Complement Med 2006; 12: 517-527 [PMID: 16884342 DOI: 10.1089/ acm.2006.12.517]
54. Webb AN, Kukuruzovic RH, Catto-Smith AG, Sawyer SM. Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2007; (4): CD005110 [PMID: 17943840 DOI: 10.1002/14651858.CD005110.pub2]
55. Roberts L, Wilson S, Singh S, Roalfe A, Greenfield S. Gutdirected hypnotherapy for irritable bowel syndrome: piloting a primary care-based randomised controlled trial. Br J Gen Pract 2006; 56: 115-121 [PMID: 16464325]
56. Zijdenbos IL, de Wit NJ, van der Heijden GJ, Rubin G, Quartero AO. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev 2009; (1): CD006442 [PMID: 19160286 DOI: 10.1002/14651858.CD006442.pub2]
57. Hutton JM. Issues to consider in cognitive-behavioural therapy for irritable bowel syndrome. Eur J Gastroenterol Hepatol 2008; 20: 249-251 [PMID: 18334865 DOI: 10.1097/ MEG.0b013e3282f25185]
58. Halpert A, Godena E. Irritable bowel syndrome patients' perspectives on their relationships with healthcare providers. Scand J Gastroenterol 2011; 46: 823-830 [PMID: 21561228 DOI: 10.3109/00365521.2011.574729]
59. Conboy LA, Macklin E, Kelley J, Kokkotou E, Lembo A, Kaptchuk T. Which patients improve: characteristics increasing sensitivity to a supportive patient-practitioner relationship. Soc Sci Med 2010; 70: 479-484 [PMID: 19900742 DOI: 10.1016/j.socscimed.2009.10.024]
60. Lang L. The Food and Drug Administration approves lubiprostone for irritable bowel syndrome with constipation. Gastroenterology 2008; 135: 7 [PMID: 18541153]
61. Sweetser S, Busciglio IA, Camilleri M, Bharucha AE, Szarka LA, Papathanasopoulos A, Burton DD, Eckert DJ, Zinsmeister AR. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol 2009; 296: G295-G301 [PMID: 19033530]
62. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009; 104: 1831-1843; quiz 1844 [PMID: 19471254 DOI: 10.1038/ajg.2009.223]
63. Thompson CA. Novartis suspends tegaserod sales at FDA' s request. Am J Health Syst Pharm 2007; 64: 1020 [PMID: 17494895]
64. Cremonini F, Nicandro JP, Atkinson V, Shringarpure R, Chuang E, Lembo A. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther 2012; 36: 437-448 [PMID: 22779693 DOI: 10.1111/j.1365-2036.2012.05208.x]
65. Bleser S. Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes. Curr Med Res Opin 2011; 27: 503-512 [PMID: 21208139 DOI: 10.118 5/03007995.2010.547933]
66. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-2131 [PMID: 12454866]
67. Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA, Gutiérrez-Udave R, Maldonado-Garza HJ, Bosques-Padilla FJ. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex 2012; 77: 82-90 [PMID: 22672854 DOI: 10.1016/ j.rgmx.2012.04.002]
68. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011; (8): CD003460 [PMID: 21833945 DOI: 10.1002/14651858.CD003460.pub3]
69. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010; 16: 547-553 [PMID: 20128021]
70. Hanauer SB. The benefits of loperamide in the treatment of patients with IBS or IBD. Introduction. Rev Gastroenterol Disord 2007; 7 Suppl 3: S1-S2 [PMID: 18192960]
71. Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology 1980; 79: 1272-1275 [PMID: 7002706]
72. Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World J Gastroenterol 2009; 15: 3591-3596 [PMID: 19653335]
73. Pimentel M, Morales W, Jee SR, Low K, Hwang L, Pokkunuri V, Mirocha J, Conklin J, Chang C. Antibiotic prophylaxis prevents the development of a post-infectious phenotype in a new rat model of post-infectious IBS. Dig Dis Sci 2011; 56: 1962-1966 [PMID: 21222158 DOI: 10.1007/s10620-010-1548-z]
74. Basseri RJ, Weitsman S, Barlow GM, Pimentel M. Antibiotics for the treatment of irritable bowel syndrome. Gastroenterol Hepatol (N Y) 2011; 7: 455-493 [PMID: 22298980]
75. Corinaldesi R, Stanghellini V, Cremon C, Gargano L, Cogliandro RF, De Giorgio R, Bartesaghi G, Canovi B, Barbara G. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proofof-concept study. Aliment Pharmacol Ther 2009; 30: 245-252 [PMID: 19438846]
76. Huerta C, García Rodríguez LA, Wallander MA, Johansson S. Users of oral steroids are at a reduced risk of developing irritable bowel syndrome. Pharmacoepidemiol Drug Saf 2003; 12: 583-588 [PMID: 14558181]
77. Róka R, Ait-Belgnaoui A, Salvador-Cartier C, Garcia-Villar R, Fioramonti J, Eutamène H, Bueno L. Dexamethasone prevents visceral hyperalgesia but not colonic permeability increase induced by luminal protease-activated receptor-2 agonist in rats. Gut 2007; 56: 1072-1078 [PMID: 17309885]
78. Rezaie A, Nikfar S, Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis. Arch Med Sci 2010; 6: 49-55
79. Frissora CL, Cash BD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 2007; 25: 1271-1281 [PMID: 17509095]
80. Saadi M, McCallum RW. Rifaximin in irritable bowel syndrome: rationale, evidence and clinical use. Ther Adv Chronic Dis 2013; 4: 71-75 [PMID: 23556126 DOI: 10.1177/204062231 2472008]
81. Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. World J Gastroenterol 2009; 15: 2628-2631 [PMID: 19496193]
82. Halland M, Talley NJ. New treatments for IBS. Nat Rev Gastroenterol Hepatol 2013; 10: 13-23 [PMID: 23147658 DOI: 10.1038/nrgastro.2012.207]
83. Shi J, Tong Y, Shen JG, Li HX. Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: a systematic review. World J Gastroenterol 2008; 14: 454-462 [PMID: 18200670]
84. Liu JP, Yang M, Liu YX, Wei M, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006; (1): CD004116 [PMID: 16437473]
85. van Tilburg MA, Palsson OS, Levy RL, Feld AD, Turner MJ, Drossman DA, Whitehead WE. Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO. BMC Complement Altern Med 2008; 8: 46 [PMID: 18652682]
86. Fisher P, van Haselen R, Hardy K, Berkovitz S, McCarney R. Effectiveness gaps: a new concept for evaluating health service and research needs applied to complementary and alternative medicine. J Altern Complement Med 2004; 10: 627-632 [PMID: 15353018 DOI: 10.1089/acm.2004.10.627]
87. Kong SC, Hurlstone DP, Pocock CY, Walkington LA, Farquharson NR, Bramble MG, McAlindon ME, Sanders DS. The Incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol 2005; 39: 138-141 [PMID: 15681910]
88. Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1998; 280: 1585-1589 [PMID: 9820260]
89. Drisko J, Bischoff B, Hall M, McCallum R. Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics. J Am Coll Nutr 2006; 25: 514-522 [PMID: 17229899]
90. Kim YJ, Ban DJ. Prevalence of irritable bowel syndrome, influence of lifestyle factors and bowel habits in Korean college students. Int J Nurs Stud 2005; 42: 247-254 [PMID: 15708012 DOI: 10.1016/j.ijnurstu.2004.06.015]
91. Levy RL, Linde JA, Feld KA, Crowell MD, Jeffery RW. The association of gastrointestinal symptoms with weight, diet, and exercise in weight-loss program participants. Clin Gastroenterol Hepatol 2005; 3: 992-996 [PMID: 16234045]
92. Rao AS, Camilleri M, Eckert DJ, Busciglio I, Burton DD, Ryks M, Wong BS, Lamsam J, Singh R, Zinsmeister AR. Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls. Am J Physiol Gastrointest Liver Physiol 2011; 301: G919-G928 [PMID: 21836056 DOI: 10.1152/ajpgi.00168.2011]
93. Saberi-Firoozi M, Khademolhosseini F, Mehrabani D, Yousefi M, Salehi M, Heidary ST. Subjective lactose intolerance in apparently healthy adults in southern Iran: Is it related to irritable bowel syndrome? Indian J Med Sci 2007; 61: 591-597 [PMID: 18025745]
94. Gupta D, Ghoshal UC, Misra A, Misra A, Choudhuri G, Singh K. Lactose intolerance in patients with irritable bowel syndrome from northern India: a case-control study. J Gastroenterol Hepatol 2007; 22: 2261-2265 [PMID: 17559357 DOI: 10.1111/j.1440-1746.2007.04986.x]
95. Yang J, Deng Y, Chu H, Cong Y, Zhao J, Pohl D, Misselwitz B, Fried M, Dai N, Fox M. Prevalence and presentation of lactose intolerance and effects on dairy product intake in healthy subjects and patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013; 11: 262-268. e1 [PMID: 23246646 DOI: 10.1016/j.cgh.2012.11.034]
96. Bijkerk CJ, Muris JW, Knottnerus JA, Hoes AW, de Wit NJ. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 19: 245-251 [PMID: 14984370]
97. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313 [PMID: 19008265]
98. Daley AJ, Grimmett C, Roberts L, Wilson S, Fatek M, Roalfe A, Singh S. The effects of exercise upon symptoms and quality of life in patients diagnosed with irritable bowel syndrome: a randomised controlled trial. Int J Sports Med 2008; 29: 778-782 [PMID: 18461499]
99. Villoria A, Serra J, Azpiroz F, Malagelada JR. Physical activity and intestinal gas clearance in patients with bloating. Am J Gastroenterol 2006; 101: 2552-2557 [PMID: 17029608]
100. Lustyk MK, Jarrett ME, Bennett JC, Heitkemper MM. Does a physically active lifestyle improve symptoms in women with irritable bowel syndrome? Gastroenterol Nurs 2001; 24: 129-137 [PMID: 11847862]
101. Kuttner L, Chambers CT, Hardial J, Israel DM, Jacobson K, Evans K. A randomized trial of yoga for adolescents with irritable bowel syndrome. Pain Res Manag 2006; 11: 217-223 [PMID: 17149454]
102. Taneja I, Deepak KK, Poojary G, Acharya IN, Pandey RM, Sharma MP. Yogic versus conventional treatment in diarrhea-predominant irritable bowel syndrome: a randomized control study. Appl Psychophysiol Biofeedback 2004; 29: 19-33 [PMID: 15077462]
103. Koch TR. Peppermint oil and irritable bowel syndrome. Am J Gastroenterol 1998; 93: 2304-2305 [PMID: 9820429 DOI: 10.1111/j.1572-0241.1998.02304.x]
104. Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Entericcoated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997; 32: 765-768 [PMID: 9430014]
105. Logan AC, Beaulne TM. The treatment of small intestinal bacterial overgrowth with enteric-coated peppermint oil: a case report. Altern Med Rev 2002; 7: 410-417 [PMID: 12410625]
106. Rees WD, Evans BK, Rhodes J. Treating irritable bowel syndrome with peppermint oil. Br Med J 1979; 2: 835-836 [PMID: 389344]
107. Sagduyu K. Peppermint oil for irritable bowel syndrome. Psychosomatics 2002; 43: 508-509 [PMID: 12444241 DOI: 10.1176/appi.psy.43.6.508]
108. Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis 2007; 39: 530-536 [PMID: 17420159 DOI: 10.1016/j.dld.2007.02.006]
109. Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R. The effect of enteric-coated, delayedrelease peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010; 55: 1385-1390 [PMID: 19507027 DOI: 10.1007/ s10620-009-0854-9]
110. Alam MS, Roy PK, Miah AR, Mollick SH, Khan MR, Mahmud MC, Khatun S. Efficacy of Peppermint oil in diarrhea predominant IBS-a double blind randomized placebo-controlled study. Mymensingh Med J 2013; 22: 27-30 [PMID: 23416804]
111. Charrois TL, Hrudey J, Gardiner P, Vohra S. Peppermint oil. Pediatr Rev 2006; 27: e49-e51 [PMID: 16815990]
112. McKay DL, Blumberg JB. A review of the bioactivity and potential health benefits of chamomile tea (Matricaria recutita L.). Phytother Res 2006; 20: 519-530 [PMID: 16628544 DOI: 10.1002/ptr.1900]
113. Walker AF, Middleton RW, Petrowicz O. Artichoke leaf extract reduces symptoms of irritable bowel syndrome in a post-marketing surveillance study. Phytother Res 2001; 15: 58-61 [PMID: 11180525]
114. Bundy R, Walker AF, Middleton RW, Marakis G, Booth JC. Artichoke leaf extract reduces symptoms of irritable bowel syndrome and improves quality of life in otherwise healthy volunteers suffering from concomitant dyspepsia: a subset analysis. J Altern Complement Med 2004; 10: 667-669 [PMID: 15353023 DOI: 10.1089/acm.2004.10.667]
115. Verspohl EJ, Ploch M, Windeck T, Klaes M, Schmidt T, Bauer K. Effect of two artichoke extracts (36_U and 36_EB) on rat ileum (with respect to bowel syndrome) and the peristaltic threshold. Phytomedicine 2008; 15: 1002-1009 [PMID: 18424104 DOI: 10.1016/j.phymed.2008.02.011]
116. Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med 2004; 10: 1015-1018 [PMID: 15673996 DOI: 10.1089/acm.2004.10]
117. Brinkhaus B, Hentschel C, Von Keudell C, Schindler G, Lindner M, Stützer H, Kohnen R, Willich SN, Lehmacher W, Hahn EG. Herbal medicine with curcuma and fumitory in the treatment of irritable bowel syndrome: a randomized, placebo-controlled, double-blind clinical trial. Scand J Gastroenterol 2005; 40: 936-943 [PMID: 16173134]
118. Rösch W, Vinson B, Sassin I. A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol 2002; 40: 401-408 [PMID: 12055663 DOI: 10.1055/s-2002-32130]
119. von Arnim U, Peitz U, Vinson B, Gundermann KJ, Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007; 102: 1268-1275 [PMID: 17531013]
120. Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multicentre trial. Aliment Pharmacol Ther 2004; 19: 271-279 [PMID: 14984373]
121. Simmen U, Kelber O, Okpanyi SN, Jaeggi R, Bueter B, Weiser D. Binding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. Phytomedicine 2006; 13 Suppl 5: 51-55 [PMID: 16973340 DOI: 10.1016/j.phymed.2006.03.012]
122. Ottillinger B, Storr M, Malfertheiner P, Allescher HD. STW 5 (Iberogast®)--a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163: 65-72 [PMID: 23263639 DOI: 10.1007/ s10354-012-0169-x]
123. Sallon S, Ben-Arye E, Davidson R, Shapiro H, Ginsberg G, Ligumsky M. A novel treatment for constipation-predominant irritable bowel syndrome using Padma Lax, a Tibetan herbal formula. Digestion 2002; 65: 161-171 [PMID: 12138321]
124. Hofbauer S, Kainz V, Golser L, Klappacher M, Kiesslich T, Heidegger W, Krammer B, Hermann A, Weiger TM. Antiproliferative properties of Padma Lax and its components ginger and elecampane. Forsch Komplementmed 2006; 13 Suppl 1: 18-22 [PMID: 16582559 DOI: 10.1159/000091147]
125. Gschossmann JM, Krayer M, Flogerzi B, Balsiger BM. Effects of the Tibetan herbal formula Padma Lax on visceral nociception and contractility of longitudinal smooth muscle in a rat model. Neurogastroenterol Motil 2010; 22: 1036-1041, e269-e270 [PMID: 20518857 DOI: 10.1111/ j.1365-2982.2010.01512.x]
126. Wang ZJ, Li HX, Wang JH, Zhang F. Effect of Shugan Jianpi Granule () on gut mucosal serotonin-positive cells in patients with irritable bowel syndrome of stagnated Ganqi attacking Pi syndrome type. Chin J Integr Med 2008; 14: 185-189 [PMID: 18853113 DOI: 10.1007/s11655-008-9001-2]
127. Pan F, Zhang T, Zhang YH, Xu JJ, Chen FM. Effect of Tongxie Yaofang Granule in treating diarrhea-predominate irritable bowel syndrome. Chin J Integr Med 2009; 15: 216-219 [PMID: 19568715 DOI: 10.1007/s11655-009-0216-7]
128. Bian Z, Wu T, Liu L, Miao J, Wong H, Song L, Sung JJ. Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review. J Altern Complement Med 2006; 12: 401-407 [PMID: 16722791 DOI: 10.1089/acm.2006.12.401]
129. Leung WK, Wu JC, Liang SM, Chan LS, Chan FK, Xie H, Fung SS, Hui AJ, Wong VW, Che CT, Sung JJ. Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial. Am J Gastroenterol 2006; 101: 1574-1580 [PMID: 16863563 DOI: 10.1111/j.1572-0241.2006.00576.x]
130. Medicine NCfCaA. What is complementary and alternative medicine? 2011. Available from: URL: http://www.nccam. nih.gov/health/whatiscam
131. Mehling WE, Wrubel J, Daubenmier JJ, Price CJ, Kerr CE, Silow T, Gopisetty V, Stewart AL. Body Awareness: a phenomenological inquiry into the common ground of mindbody therapies. Philos Ethics Humanit Med 2011; 6: 6 [PMID: 21473781 DOI: 1747-5341-6-6]
132. Eriksson EM, Möller IE, Söderberg RH, Eriksson HT, Kurlberg GK. Body awareness therapy: a new strategy for relief of symptoms in irritable bowel syndrome patients. World J Gastroenterol 2007; 13: 3206-3214 [PMID: 17589899]
133. Johannesson E, Simrén M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 2011; 106: 915-922 [PMID: 21206488 DOI: 10.1038/ajg.2010.480]
134. Tovey P. A single-blind trial of reflexology for irritable bowel syndrome. Br J Gen Pract 2002; 52: 19-23 [PMID: 11791811]
135. Cherniack EP. Use of complementary and alternative medicine to treat constipation in the elderly. Geriatr Gerontol Int 2013; 13: 533-538 [PMID: 23294466 DOI: 10.1111/ggi.12023]
136. Lämås K, Graneheim UH, Jacobsson C. Experiences of abdominal massage for constipation. J Clin Nurs 2012; 21: 757-765 [PMID: 22098585 DOI: 10.1111/j.1365-2702.2011.03946.x]
137. Harrington KL, Haskvitz EM. Managing a patient's constipation with physical therapy. Phys Ther 2006; 86: 1511-1519 [PMID: 17079751 DOI: 10.2522/ptj.20050347]
138. Zhou EH, Liu HR, Wu HG, Shi Y, Wang XM, Tan LY, Yao LQ, Zhong YS, Jiang Y, Zhang LL. Suspended moxibustion relieves chronic visceral hyperalgesia via serotonin pathway in the colon. Neurosci Lett 2009; 451: 144-147 [PMID: 19114087 DOI: 10.1016/j.neulet.2008.12.026]
139. Tian SL, Wang XY, Ding GH. Repeated electro-acupuncture attenuates chronic visceral hypersensitivity and spinal cord NMDA receptor phosphorylation in a rat irritable bowel syndrome model. Life Sci 2008; 83: 356-363 [PMID: 18694764 DOI: 10.1016/j.lfs.2008.06.027]
140. Ma XP, Tan LY, Yang Y, Wu HG, Jiang B, Liu HR, Yang L. Effect of electro-acupuncture on substance P, its receptor and corticotropin-releasing hormone in rats with irritable bowel syndrome. World J Gastroenterol 2009; 15: 5211-5217 [PMID: 19891022]
141. Vas J, Rivas-Ruiz F. Response to letter by Wu and Guo. Pain 2013; 154: 2576 [PMID: 23988366 DOI: 10.1016/ j.pain.2013.08.021]
142. Kong J, Spaeth R, Cook A, Kirsch I, Claggett B, Vangel M, Gollub RL, Smoller JW, Kaptchuk TJ. Are all placebo effects equal? Placebo pills, sham acupuncture, cue conditioning and their association. PLoS One 2013; 8: e67485 [PMID: 23935833 DOI: 10.1371/journal.pone.0067485]
143. Lembo AJ, Conboy L, Kelley JM, Schnyer RS, McManus CA, Quilty MT, Kerr CE, Drossman D, Jacobson EE, Davis RB. A treatment trial of acupuncture in IBS patients. Am J Gastroenterol 2009; 104: 1489-1497 [PMID: 19455132 DOI: 10.1038/ajg.2009.156]
144. Schneider A, Enck P, Streitberger K, Weiland C, Bagheri S, Witte S, Friederich HC, Herzog W, Zipfel S. Acupuncture treatment in irritable bowel syndrome. Gut 2006; 55: 649-654 [PMID: 16150852 DOI: 10.1136/gut.2005.074518]
145. Schneider A, Streitberger K, Joos S. Acupuncture treatment in gastrointestinal diseases: a systematic review. World J Gastroenterol 2007; 13: 3417-3424 [PMID: 17659687]
146. Anastasi JK, McMahon DJ, Kim GH. Symptom management for irritable bowel syndrome: a pilot randomized controlled trial of acupuncture/moxibustion. Gastroenterol Nurs 2009; 32: 243-255 [PMID: 19696601 DOI: 10.1097/ SGA.0b013e3181b2c920]
147. Lim B, Manheimer E, Lao L, Ziea E, Wisniewski J, Liu J, Berman B. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006; (4): CD005111 [PMID: 17054239]
148. Field T. Yoga clinical research review. Complement Ther Clin Pract 2011; 17: 1-8 [PMID: 21168106 DOI: 10.1016/ j.ctcp.2010.09.007]
149. Brands MM, Purperhart H, Deckers-Kocken JM. A pilot study of yoga treatment in children with functional abdominal pain and irritable bowel syndrome. Complement Ther Med 2011; 19: 109-114 [PMID: 21641514 DOI: 10.1016/ j.ctim.2011.05.004]
150. Cuellar NG. Hypnosis for pain management in the older adult. Pain Manag Nurs 2005; 6: 105-111 [PMID: 16129381 DOI: 10.1016/j.pmn.2005.05.004]
151. Hrezo RJ. Hypnosis: an alternative in pain management for nurse practitioners. Nurse Pract Forum 1998; 9: 217-226 [PMID: 10214224]
152. Rainville P, Hofbauer RK, Paus T, Duncan GH, Bushnell MC, Price DD. Cerebral mechanisms of hypnotic induction and suggestion. J Cogn Neurosci 1999; 11: 110-125 [PMID: 9950718]
153. Abrahamsen R, Baad-Hansen L, Zachariae R, Svensson P. Effect of hypnosis on pain and blink reflexes in patients with painful temporomandibular disorders. Clin J Pain 2011; 27: 344-351 [PMID: 21178599 DOI: 10.1097/ AJP.0b013e3181ffbfcb]
154. Lea R, Houghton LA, Calvert EL, Larder S, Gonsalkorale WM, Whelan V, Randles J, Cooper P, Cruickshanks P, Miller V, Whorwell PJ. Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 635-642 [PMID: 12641511]
155. Gonsalkorale WM, Miller V, Afzal A, Whorwell PJ. Long term benefits of hypnotherapy for irritable bowel syndrome. Gut 2003; 52: 1623-1629 [PMID: 14570733]
156. Gonsalkorale WM. Gut-directed hypnotherapy: the Manchester approach for treatment of irritable bowel syndrome. Int J Clin Exp Hypn 2006; 54: 27-50 [PMID: 16316882 DOI: 10.1080/00207140500323030]
157. Gonsalkorale WM, Toner BB, Whorwell PJ. Cognitive change in patients undergoing hypnotherapy for irritable bowel syndrome. J Psychosom Res 2004; 56: 271-278 [PMID: 15046962 DOI: 10.1016/s0022-3999(03)00076-x]
158. Palsson OS, Turner MJ, Johnson DA, Burnett CK, Whitehead WE. Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms. Dig Dis Sci 2002; 47: 2605-2614 [PMID: 12452403]
159. Vlieger AM, Menko-Frankenhuis C, Wolfkamp SC, Tromp E, Benninga MA. Hypnotherapy for children with functional abdominal pain or irritable bowel syndrome: a randomized controlled trial. Gastroenterology 2007; 133: 1430-1436 [PMID: 17919634 DOI: 10.1053/j.gastro.2007.08.072]
160. Lindfors P, Ljótsson B, Bjornsson E, Abrahamsson H, Simrén M. Patient satisfaction after gut-directed hypnotherapy in irritable bowel syndrome. Neurogastroenterol Motil 2013; 25: 169-e86 [PMID: 23051178 DOI: 10.1111/nmo.12022]
161. Lindfors P, Unge P, Arvidsson P, Nyhlin H, Björnsson E, Abrahamsson H, Simrén M. Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials. Am J Gastroenterol 2012; 107: 276-285 [PMID: 21971535 DOI: 10.1038/ajg.2011.340]
162. Moser G, Trägner S, Gajowniczek EE, Mikulits A, Michalski M, Kazemi-Shirazi L, Kulnigg-Dabsch S, Führer M, Ponocny-Seliger E, Dejaco C, Miehsler W. Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 2013; 108: 602-609 [PMID: 23419384 DOI: 10.1038/ajg.2013.19]
163. Gerson CD, Gerson J, Gerson MJ. Group hypnotherapy for irritable bowel syndrome with long-term follow-up. Int J Clin Exp Hypn 2013; 61: 38-54 [PMID: 23153384 DOI: 10.1080 /00207144.2012.700620]
164. Lindfors P, Unge P, Nyhlin H, Ljótsson B, Björnsson ES, Abrahamsson H, Simrén M. Long-term effects of hypnotherapy in patients with refractory irritable bowel syndrome. Scand J Gastroenterol 2012; 47: 414-420 [PMID: 22339617 DOI: 10.3109/00365521.2012.658858]
165. Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitive-behavioral therapy: a review of metaanalyses. Clin Psychol Rev 2006; 26: 17-31 [PMID: 16199119 DOI: 10.1016/j.cpr.2005.07.003]
166. Tsiros MD, Sinn N, Brennan L, Coates AM, Walkley JW, Petkov J, Howe PR, Buckley JD. Cognitive behavioral therapy improves diet and body composition in overweight and obese adolescents. Am J Clin Nutr 2008; 87: 1134-1140 [PMID: 18469231]
167. Turner JA, Holtzman S, Mancl L. Mediators, moderators, and predictors of therapeutic change in cognitive-behavioral therapy for chronic pain. Pain 2007; 127: 276-286 [PMID: 17071000 DOI: 10.1016/j.pain.2006.09.005]
168. Thase ME, Dubé S, Bowler K, Howland RH, Myers JE, Friedman E, Jarrett DB. Hypothalamic-pituitary-adrenocortical activity and response to cognitive behavior therapy in unmedicated, hospitalized depressed patients. Am J Psychiatry 1996; 153: 886-891 [PMID: 8659610]
169. Vitiello MV, Rybarczyk B, Von Korff M, Stepanski EJ. Cognitive behavioral therapy for insomnia improves sleep and decreases pain in older adults with co-morbid insomnia and osteoarthritis. J Clin Sleep Med 2009; 5: 355-362 [PMID: 19968014]
170. Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, Emmott S, Proffitt V, Akman D, Frusciante K, Le T, Meyer K, Bradshaw B, Mikula K, Morris CB, Blackman CJ, Hu Y, Jia H, Li JZ, Koch GG, Bangdiwala SI. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125: 19-31 [PMID: 12851867]
171. Weinland SR, Morris CB, Dalton C, Hu Y, Whitehead WE, Toner BB, Diamant N, Leserman J, Bangdiwala SI, Drossman DA. Cognitive factors affect treatment response to medical and psychological treatments in functional bowel disorders. Am J Gastroenterol 2010; 105: 1397-1406 [PMID: 20087332 DOI: 10.1038/ajg.2009.748]
172. Jones M, Koloski N, Boyce P, Talley NJ. Pathways connecting cognitive behavioral therapy and change in bowel symptoms of IBS. J Psychosom Res 2011; 70: 278-285 [PMID: 21334499 DOI: 10.1016/j.jpsychores.2010.10.004]
173. Ljótsson B, Hedman E, Andersson E, Hesser H, Lindfors P, Hursti T, Rydh S, Rück C, Lindefors N, Andersson G. Internet-delivered exposure-based treatment vs. stress management for irritable bowel syndrome: a randomized trial. Am J Gastroenterol 2011; 106: 1481-1491 [PMID: 21537360 DOI: 10.1038/ajg.2011.139]
174. Kennedy TM, Chalder T, McCrone P, Darnley S, Knapp M, Jones RH, Wessely S. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial. Health Technol Assess 2006; 10: iii-iv, ix-x, 1-67 [PMID: 16729918]
175. Mahvi-Shirazi M, Fathi-Ashtiani A, Rasoolzade-Tabatabaei S-K, Amini M. Irritable bowel syndrome treatment: cognitive behavioral therapy versus medical treatment. Arch Med Sci 2008; 8: 123-129
176. Tkachuk GA, Graff LA, Martin GL, Bernstein CN. Randomized controlled trial of Cognitive-Behavioral Group Therapy for Irritable Bowel Syndrome in a Medical Setting. J Clin Psych Med Set 2003; 10: 57-69
177. Craske MG, Wolitzky-Taylor KB, Labus J, Wu S, Frese M, Mayer EA, Naliboff BD. A cognitive-behavioral treatment for irritable bowel syndrome using interoceptive exposure to visceral sensations. Behav Res Ther 2011; 49: 413-421 [PMID: 21565328 DOI: 10.1016/j.brat.2011.04.001]
178. Lackner JM, Keefer L, Jaccard J, Firth R, Brenner D, Bratten J, Dunlap LJ, Ma C, Byroads M. The Irritable Bowel Syndrome Outcome Study (IBSOS): rationale and design of a randomized, placebo-controlled trial with 12 month follow up of self-versus clinician-administered CBT for moderate to severe irritable bowel syndrome. Contemp Clin Trials 2012; 33: 1293-1310 [PMID: 22846389 DOI: 10.1016/j.cct.2012.07.013]
179. Ljótsson B, Falk L, Vesterlund AW, Hedman E, Lindfors P, Rück C, Hursti T, Andréewitch S, Jansson L, Lindefors N, Andersson G. Internet-delivered exposure and mindfulness based therapy for irritable bowel syndrome--a randomized controlled trial. Behav Res Ther 2010; 48: 531-539 [PMID: 20362976 DOI: 10.1016/j.brat.2010.03.003]
180. Gaylord SA, Palsson OS, Garland EL, Faurot KR, Coble RS, Mann JD, Frey W, Leniek K, Whitehead WE. Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial. Am J Gastroenterol 2011; 106: 1678-1688 [PMID: 21691341 DOI: 10.1038/ajg.2011.184]
181. Ljótsson B, Hedman E, Lindfors P, Hursti T, Lindefors N, Andersson G, Rück C. Long-term follow-up of internetdelivered exposure and mindfulness based treatment for irritable bowel syndrome. Behav Res Ther 2011; 49: 58-61 [PMID: 21092934 DOI: 10.1016/j.brat.2010.10.006]
182. Tillisch K. Complementary and alternative medicine for functional gastrointestinal disorders. Gut 2006; 55: 593-596 [PMID: 16609129 DOI: 10.1136/gut.2005.078089]
183. Birtwhistle RV. Irritable bowel syndrome: are complementary and alternative medicine treatments useful? Can Fam Physician 2009; 55: 126-127, 128-129 [PMID: 19221064]
184. Shen YH, Nahas R. Complementary and alternative medicine for treatment of irritable bowel syndrome. Can Fam Physician 2009; 55: 143-148 [PMID: 19221071]
185. CAHCIM. AHC-Consortium of Academic Health Centers for Integrative Medicine 2013. Available from: URL: http:// www.imconsortium.org/